← All trials
NCT05857163
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 18, 2023
- Primary completion
- May 30, 2024
- Completion date
- Oct 30, 2024
- First posted
- May 12, 2023
- Last posted
- Jun 15, 2023
- Enrollment
- 700
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- TenNor Therapeutics LtdLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.